Favipiravir
- PDF / 151,237 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 52 Downloads / 170 Views
1 S
Hyperuricaemia and acute gouty arthritis following off-label use: case report A 42-year-old man developed hyperuricaemia and acute gouty arthritis following off-label use of favipiravir for coronavirus disease 2019 (COVID-19). The man presented with a 1-week history of shortness of breath, a fever and general malaise. His medical history was significant for gout attack, type 2 diabetes, hyperlipidaemia and hyperuricaemia. He was receiving alogliptin [alogliptin benzoate], febuxostat, luseogliflozin and rosuvastatin treatment. His hyperuricaemia was well controlled, without any gout attack for more than a year. On day 3 of hospitalisation, he was found to be positive for COVID-19, and started on compassionate use of oral favipiravir 1800mg two times a day on day 1 of administration, followed by 800mg two times a day from day 2 to day 14. On day 5 of hospitalisation, his fever ameliorated, and all of his symptoms disappeared. However, on day 13 of admission, his uric acid level increased (hyperuricaemia). Therapy with favipiravir was maintained for 2 weeks until day 16 of hospitalisation. On day 15 of admission, he experienced pain on his left foot. A physical examination showed a reddish and swollen left metatarsophalangeal joint. A clinical diagnosis of acute gouty arthritis was considered, and the man was prescribed unspecified NSAIDs. The swelling and pain ameliorated until day 20 of hospital stay. Subsequently, he recovered and was discharged on day 22 of hospitalisation. Hase R, et al. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019. Internal Medicine 59: 2327-2329, No. 18, 15 Sep 2020. Available from: 803506645 URL: http://doi.org/10.2169/internalmedicine.5377-20
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
